Comments on: Pfizer Inc. (PFE) http://stockherd.com/moosepond/2005/07/pfizer-inc/ Online Journal for the Moose Pond Investors Club Tue, 12 Feb 2008 02:58:15 +0000 hourly 1 http://wordpress.org/?v=3.0 By: Anonymous http://stockherd.com/moosepond/2005/07/pfizer-inc/comment-page-1/#comment-13 Anonymous Sun, 31 Jul 2005 02:04:05 +0000 http://stockherd.com/moosepond/?p=57#comment-13 Susan: I would say that 2003 and 2004 are definitely atypical for PFE. Despite the recent reduction is sales growth, PFE seems to have strong managment, plenty of cash and a pipeline of new drugs. Also, it is at an all time low PE (around 22). I am compfortable buying it. There were several posts on the NAIC CompuServe forum on this same topic. - Ty H. Susan: I would say that 2003 and 2004 are definitely atypical for PFE. Despite the recent reduction is sales growth, PFE seems to have strong managment, plenty of cash and a pipeline of new drugs. Also, it is at an all time low PE (around 22). I am compfortable buying it. There were several posts on the NAIC CompuServe forum on this same topic. – Ty H.

]]> By: Anonymous http://stockherd.com/moosepond/2005/07/pfizer-inc/comment-page-1/#comment-12 Anonymous Wed, 27 Jul 2005 21:19:24 +0000 http://stockherd.com/moosepond/?p=57#comment-12 Ty, are we looking at year 2003 as an outlier? What about the last several quarters? Is this solely due to the recall of the Cox II inhibitors? With an anemic return of 1.2 percent in sales, and moving forward expiration in several patents, it will make sense to take a wait see attitude to see what pans out from the R&D pipeline. Susan Ty, are we looking at year 2003 as an outlier? What about the last several quarters? Is this solely due to the recall of the Cox II inhibitors? With an anemic return of 1.2 percent in sales, and moving forward expiration in several patents, it will make sense to take a wait see attitude to see what pans out from the R&D pipeline.

Susan

]]>